SMTI — SANARA MEDTECH INC (Healthcare >> Medical Instruments & Supplies)
SMTI FAQ
What is SMTI's P/E ratio?
SANARA MEDTECH INC (SMTI) currently trades at a P/E ratio of 158.99.
What is SMTI's ROE?
SANARA MEDTECH INC reports a Return on Equity (ROE) of -477.72%.
What is SMTI's dividend yield?
SANARA MEDTECH INC offers a dividend yield of 0.00%.
What is SMTI's Deepscope Quality Score?
Deepscope rates SMTI's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy SMTI?
Deepscope's AI Timing Score for SMTI is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does SMTI belong to?
SANARA MEDTECH INC is classified under the Healthcare >> Medical Instruments & Supplies sector on the NASDAQ exchange.
|
USD 22.72
Price
0.63
(2.85%)
Day Change
|
|
|---|
SMTI, the overall quality is not good ( Quality = 46) but the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 88 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 22.72 |
| PBV / Sector |
29.30 / 4.11
|
| Earning Per Share | -3.71 |
| PE / Sector |
158.99 / 36.69
|
| PEG or PE/Growth / Sector |
1.35 / -0.88
|
| Average 1M Daily Value |
1.13 M
GREAT
|
| Average 1W Daily Value |
1.11 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
60% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-10 09:43:54 |
| Symbol | SMTI |
| Name | SANARA MEDTECH INC |
| Sector | Healthcare >> Medical Instruments & Supplies |
| Market | NASDAQ |
| Listed Shares | 9.16 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 205.64 / 16,930.79 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1200 Summit Avenue, Fort Worth, TX, United States, 76102
Phone: 817 529 2300
Website: https://sanaramedtech.com
Employees: 108
Description: Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY Tissue Repair Graft(FORTIFY TRG), a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; BiFORM, an osteoconductive, bioactive, porous implant that allows bony ingrowth across the graft site and it can be used as a strip or molded into a putty to fill a bone defect; ACTIGEN Inductive Bone Matrix, a naturally derived, differentiated allograft matrix with robust handling properties; ALLOCYTE Plus, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
ME vs SECTOR Healthcare >> Medical Instruments & Supplies
Click a bubble to view stock details · Bubble size represents market capitalization share
Google